ESC 365 - Should a decline in eGFR to <30 mL/min always lead to discontinuation of an MRA?

HFA Premium Access

Should a decline in eGFR to <30 mL/min always lead to discontinuation of an MRA?

Session: Treating heart failure with diabetes and renal disease

Topic: Pharmacotherapy

Speaker: Doctor S. Matsumoto (Tokyo, JP) Doctor L. Shen (Glasgow, CN)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speakers

Doctor Shingo Matsumoto

Toho University, Tokyo (Japan)

0 follower

Doctor Li Shen

Hanghou Normal University, Glasgow (China)

2 presentations

0 follower

6 more presentations in this session

Pharmacological treatment patterns and outcomes according to the coexistence of heart failure and type 2 diabetes. Data from the Swedish Heart Failure Registry and National Diabetes Registry

Speaker: Doctor F. Musella (Naples, IT)

Insulin therapy in patients with heart failure and type 2 diabetes: predictors of use and associations with outcomes. Data from the Swedish Heart Failure Registry and National Diabetes Registry.

Speaker: Mr M. Biber (Trieste, IT)

Deciphering mortality risk of antidiabetic medications in well-treated heart failure patients with diabetes mellitus

Speaker: Assistant Professor I. Colluoglu (Karabuk, TR)

Survival analysis in heart failure and end-stage chronic kidney disease: a propensity score matched study comparing peritoneal dialysis and hemodialysis

Speaker: Assistant Professor A. Sahin (Sivas, TR)

Discontinuation and re-initiation of mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction

Speaker: Ms L. Landucci (Stockholm, SE)

Access the full session

Treating heart failure with diabetes and renal disease

Speakers: Doctor S. Matsumoto, Doctor L. Shen, Doctor F. Musella, Mr M. Biber, Assistant Professor I. Colluoglu...

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources